Assets

Bispecific Antibody Assets

Bispecific antibodies (BsAbs) are engineered antibodies capable of simultaneously binding to two different antigens or epitopes. Compared to monoclonal antibodies and combination therapies, BsAbs demonstrate higher efficacy, lower resistance, and a broader range of applicability due to new functional capabilities. They are expected to have lower toxicity than combined monoclonal antibody treatments. As a result, BsAbs are regarded as a new generation of antibody therapies.
  • 10+
    Fully-human BsAbs
  • 10+
    TCR mimic Assets

on this page

  • Why choose Biocytogen's BsAb portfolio?
  • Our BsAb&Tri-Ab assets currently open for partnership
  • Selected assets overview
  • FAQs

Webinars

View All

    Posters

    View All

      Why choose Biocytogen's BsAb portfolio?

      • Produced by Biocytogen's proprietary RenLite mice platform and generated by size unlimited chromosome engineering technology (SUPCE), it features a diversified heavy chain sequence repertoire similar to that of humans.
      • RenLite-derived bsAbs have high binding affinity and high specificity.
      • BsAbs span multiple areas including oncology, inflammation and autoimmunity.
      • At Biocytogen, we adhere to the highest standards of quality and scientific rigor. Fully human bispecific antibodies have demonstrated excellent developability and efficacy through in vivo testing.
      • We provide multiple collaboration models, including licensing, transfer, and co-development of bsAbs, and have established partnerships with numerous industry leaders. We warmly invite you to collaborate with us for the benefit of patients worldwide!

      Our BsAb&Tri-Ab assets currently open for partnership

      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection
        Leads
        selection
        Candidate
        selection
      Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CDH17 x CD3 x CD28
      TCE Oncology - STEAP1 x CD3e
      TCE Oncology BCG024 DLL3 x CD3 x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R

      Selected assets overview

      In addition, Biocytogen also has TCR-like antibody (TCRmimic) assets used for assembling bispecific antibodies with CD3. Contact us today to explore evaluation/licensing/co-development opportunities!

      4-1BB x CD40 fully human bsAb (BCG021) for oncology
      Highlights of our assets:
      • Conditional 4-1BB and CD40 agonistic activity dependent on crosslinking of both targets
      • Potent in vivo anti-tumor activity and significantly improved tumor growth inhibition when combined with anti-PD-1 mAb
      • Desirable physicochemical properties
      • Good in vivo safety in mice
      • Antibody-like PK profile in mice
      • Patent application has been submitted

      Frequently Asked Questions (FAQs) About Bispecific Antibody Assets

      1. What therapeutic assets are available in Biocytogen’s bispecific antibody pipeline?

      Biocytogen’s pipeline includes bispecific antibodies (BsAbs), biparatopic antibodies (BpAbs), and trispecific antibodies (Tri-Abs), including diverse T-cell engager (TCE) programs. These assets span oncology, inflammation and autoimmunity, and metabolism, with more than 10 preclinical programs ready for out-licensing or partnership.

      2. What preclinical data packages are available for Biocytogen’s bispecific antibody assets?

      Depending on the program, Biocytogen’s preclinical BsAb assets are supported by data packages covering binding affinity, specificity, in vitro functional activity, in vivo efficacy in disease mouse models, PK, safety, and developability. For TCE assets, additional data include target-dependent T-cell activation and proliferation, in vitro cytotoxicity or tumor-lysis activity, and cytokine-release assessments.

      3. How does Biocytogen aim to expand the therapeutic window of next-generation T-cell engagers (TCEs) for solid tumors?

      Biocytogen designs next-generation T-cell engagers (TCEs) to expand the therapeutic window—balancing effective tumor killing at doses that remain safe and tolerable. Our approach combines tuned CD3 engagement with localized co-stimulation including 4-1BB or CD28 to sustain antitumor activity while limiting systemic immune activation and cytokine release syndrome (CRS) risk.
      For example, Biocytogen’s BCG024, a DLL3 × CD3ε × 4-1BB trispecific TCE, integrates a spatially restricted CD3 scFv with a fully human 4-1BB VHH co-stimulatory module. Preclinical findings show potent cytotoxicity with limited systemic cytokine induction, supporting its potential for a wider therapeutic window.

      4. Are Biocytogen’s bispecific antibody programs available for licensing or co-development?

      Yes. Biocytogen welcomes flexible collaboration opportunities for evaluation, licensing, technology transfer, and co-development. Partners can request program-specific data packages and discuss collaboration options aligned with their development priorities. Contact us today!

      5. What development stages does Biocytogen’s bispecific antibody pipeline cover?

      Biocytogen’s bispecific antibody portfolio spans early discovery, preclinical and clinical development. Many preclinical assets have advanced to candidate selection, and the partnered YH008 program has progressed into Phase I.
      For early-stage programs, Biocytogen offers TAA antibody binders and backbones to support customized BsAb development.